The Underappreciated Risk Of Pediatric Cannabis Overdose

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

There are major risks associated with the consumption of large amounts of cannabis by young children. Unlike in adults, the risks to children include coma and even death. Other effects include tachycardia, nausea and vomiting, and respiratory depression severe enough to require ventilation. Cannabis ingestion in children is an immediate medical emergency. The risks were recently highlighted in a segment from CBS News.

The legalization of recreational marijuana in a number of states has been linked to an increase in the overall use of cannabis products, which includes a substantial increase in the consumption of edible cannabis. The more widespread availability of edibles poses new risks of accidental exposure, especially in children. Edibles are commonly made as gummies, cookies, brownies, and other sweets that can be attractive to children, and the doses in an individual gummy, etc., in many cases exceed the average dose for an adult.

Reports from poison control centers document a substantial increase in the number of reports related to cannabis in recent years, and reports from edibles are substantially overrepresented: despite accounting for only 11.1% of cannabis sales, 48% of reports involving children under 10 were from the consumption of edibles.

Concentrates also pose an increased risk to children, because they allow for the quick, accidental consumption of very large doses. Consumption of concentrates by children makes up 11% of pediatric reports (to whom?).

There is evidence that links the increased rate of unintentional pediatric exposure to cannabis to the changing legal status of the drug. From 2005 to 2011, the rates of pediatric exposure rose 30.3% in legal states, whereas there was no change in non-legal states. Therefore, the expectation is that unintentional pediatric exposure will be a worsening problem as more regions of the country decriminalize cannabis and expand access to the drug.

A Cannabis Antidote Could Be The Solution

Anebulo Pharmaceuticals ANEB is investing in a solution to this worsening problem. The company’s lead drug ANEB-001 is an antidote to cannabis intoxication that could quickly reverse the effects of a THC and other cannabinoids in a child. ANEB-001 binds to the receptor in the brain responsible for the effects of cannabinoids (the CB1 receptor) and prevents it from being engaged by THC. This is similar in principle to how Narcan (naloxone) can be used to reverse an opioid overdose.

In addition to pediatric exposure, ANEB-001 has the potential to be used as an antidote for any instance of cannabinoid intoxication, including synthetic cannabinoids such as K2 or Spice. The company will be entering Phase II clinical studies later this year. 
 

Image by NickyPe from Pixabay

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Posted In: AnebuloediblesPartner ContentCannabisGovernmentNewsRegulationsHealth CareLegalMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.